Nidan Laborator.

Why is Nidan Laboratories & Healthcare Ltd falling/rising?

As of 20-Jul, Nidan Laboratories & Healthcare Ltd is facing a significant decline in its stock price, currently at 12.95, with a year-to-date drop of -30.56% and a staggering -72.30% decline over the past three years, reflecting poor financial health and weak investor interest. The company's high Debt to EBITDA ratio and lack of recent financial results further exacerbate concerns, leading to a strong sell sentiment among investors.

As of 20-Jul, Nidan Laboratories & Healthcare Ltd is experiencing a decline in its stock price, currently at 12.95, reflecting a change of -0.1 (-0.77%). This downward movement can be attributed to several factors highlighted in the recent performance metrics. Over the past week, the stock has underperformed significantly, with a decline of -7.17%, while the benchmark Sensex has shown a slight increase of +0.11%. <BR><BR>In the longer term, the stock's performance has been consistently poor, with a year-to-date drop of -30.56% compared to a -7.24% decline in the Sensex. The stock has also underperformed over the past year, generating a return of -36.83%, which starkly contrasts with the benchmark's -2.92% performance. Furthermore, over the last three years, Nidan Laboratories has seen a staggering decline of -72.30%, while the Sensex has increased by +21.32%.<BR><BR>Today's trading performance indicates that the stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by -79.17% against the 5-day average. This lack of interest from investors further contributes to the stock's decline.<BR><BR>Moreover, the company's financial health raises concerns, as it has not declared results in the last six months, indicating weak long-term fundamental strength. The high Debt to EBITDA ratio of 2.47 times suggests a low ability to service debt, and the average Return on Capital Employed of 9.06% indicates low profitability per unit of total capital. These factors collectively paint a picture of a struggling company, leading to a strong sell sentiment among investors and contributing to the stock's falling price.

Which are the latest news on Nidan Laborator.?

What does Nidan Laborator. do?

Nidan Laboratories & Healthcare Ltd is a micro-cap company in the hospital industry, reporting net sales of 17 Cr and a net profit of 2 Cr for September 2021. It was incorporated in 2000 and has a market cap of INR 19 Cr.

Overview: <BR>Nidan Laboratories & Healthcare Ltd operates in the hospital industry and is classified as a micro-cap company.<BR><BR>History: <BR>The company was originally incorporated as Abhi Diagnostic Imagings Private Limited in 2000. It later changed its name to Nidan Laboratories And Healthcare Private Limited, with the latest certificate of incorporation issued on March 24, 2021. The most recent quarterly results reported net sales and net profit for September 2021.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 17 Cr (Quarterly Results - Sep 2021) <BR>Most recent Net Profit: 2 Cr (Quarterly Results - Sep 2021) <BR>Market-cap value: INR 19 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.15 <BR>Return on Equity: 2.52% <BR>Price to Book: 0.28 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Nidan Laborator.?

As of 10th June, Nidan Laboratories & Healthcare Ltd has a market capitalization of 19.00 Cr, with recent net sales of 24.35 Cr and a net profit of 2.89 Cr. Shareholder's funds are valued at 68.18 Cr, and total assets amount to 82.17 Cr as of March 2025.

As of 10th June, Nidan Laboratories & Healthcare Ltd has a market capitalization of 19.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest two quarters, Nidan Laboratories reported Net Sales of 24.35 Cr and a Net Profit of 2.89 Cr. The figures reflect the company's performance for the quarters ending in September 2021 and June 2021.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds are valued at 68.18 Cr and Total Assets amount to 82.17 Cr.

Who are in the management team of Nidan Laborator.?

The management team of Nidan Laborator includes Edwin Francis Dabre (Executive Director), Tejal Anil Jayakar (Executive Director & CFO), Krupesh Deepak Thakur (Non-Executive Director), and three Independent Directors: Nilesh Ghanshyam Bide, Abhinay Shashikant Nerurkar, and Karim Hakam Khimani, along with Akshay Joshi as Company Secretary.

The management team of Nidan Laborator includes the following individuals:<BR><BR>1. **Edwin Francis Dabre** - Executive Director<BR>2. **Tejal Anil Jayakar** - Executive Director & CFO<BR>3. **Krupesh Deepak Thakur** - Non-Executive Director<BR>4. **Nilesh Ghanshyam Bide** - Independent Director<BR>5. **Abhinay Shashikant Nerurkar** - Independent Director<BR>6. **Karim Hakam Khimani** - Independent Director<BR>7. **Akshay Joshi** - Company Secretary<BR><BR>If you need more information about their roles or the company, feel free to ask!

Who are the peers of the Nidan Laborator.?

Nidan Laborator.'s peers include Maitreya Medica, Sangani Hospital, Aatmaj Health, Docmode Health, KK Shah Hospital, Soni Medicare, Global Longlife, Broach Lifecare, Shanmuga Hospital, and Fortis Malar. Most peers exhibit below average management risk and growth, with Nidan Laborator. showing a 1-year return of -38.24%.

Peers: The peers of Nidan Laborator. are Maitreya Medica., Sangani Hospital, Aatmaj Health, Docmode Health, KK Shah Hospital, Soni Medicare, Global Longlife, Broach Lifecare, Shanmuga Hos., and Fortis Malar.<BR><BR>Quality Snapshot: Below Average management risk is observed at Maitreya Medica., Sangani Hospital, Aatmaj Health, Nidan Laborator., Docmode Health, KK Shah Hospital, Soni Medicare, Broach Lifecare, and Fortis Malar, while Average management risk is found at Global Longlife and Shanmuga Hos. Excellent growth is noted at Sangani Hospital, while Below Average growth is seen at Maitreya Medica., Aatmaj Health, Nidan Laborator., Docmode Health, Soni Medicare, Global Longlife, and the rest. Good capital structure is present at Sangani Hospital, Aatmaj Health, KK Shah Hospital, Broach Lifecare, and Shanmuga Hos., while Below Average capital structure is found at Maitreya Medica., Nidan Laborator., Docmode Health, Soni Medicare, and Fortis Malar.<BR><BR>Return Snapshot: Sangani Hospital has the highest 1-year return at -35.43%, while Maitreya Medica. has the lowest at -45.96%. Nidan Laborator.'s 1-year return is -38.24%, which is better than Maitreya Medica. but worse than Sangani Hospital. Additionally, the six-month return is negative for Maitreya Medica., Sangani Hospital, Aatmaj Health, Nidan Laborator., Docmode Health, and Fortis Malar.

Should I buy, sell or hold Nidan Laboratories & Healthcare Ltd?

Is Nidan Laborator. overvalued or undervalued?

As of December 2, 2025, Nidan Laborator. is considered undervalued with a PE ratio of 15.76 and an attractive valuation grade, indicating potential for recovery despite a year-to-date return of -22.18%, especially when compared to higher PE ratios of peers like Max Healthcare and Apollo Hospitals.

As of 2 December 2025, Nidan Laborator. has moved from a fair to an attractive valuation grade, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 15.76, an EV to EBITDA of 8.27, and a Price to Book Value of 0.45. These ratios suggest that Nidan Laborator. is trading at a discount compared to its peers, particularly when compared to Max Healthcare, which has a PE ratio of 76.89, and Apollo Hospitals, with a PE of 62.27.<BR><BR>In the context of its industry, Nidan Laborator.'s valuation metrics stand out, especially given its low PEG ratio of 0.00, indicating no growth premium is being paid for future earnings. The company's return metrics, such as ROCE at 3.31% and ROE at 2.84%, further support the notion of undervaluation relative to its peers. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -22.18% compared to the Sensex's 10.10%, the attractive valuation suggests potential for recovery and growth.

How has been the historical performance of Nidan Laborator.?

Nidan Laborator's historical performance shows fluctuations, with net sales increasing slightly to 24.53 Cr in March 2025, while profit before tax rebounded to 2.76 Cr from a loss the previous year. Despite a profit recovery, cash flow from operating activities decreased to 2.00 Cr, indicating ongoing challenges.

Answer:<BR>The historical performance of Nidan Laborator shows fluctuations in key financial metrics over the years, with a notable recovery in the latest fiscal year.<BR><BR>Breakdown:<BR>Nidan Laborator's net sales for the year ending March 2025 were reported at 24.53 Cr, a slight increase from 24.18 Cr in March 2024, following a dip from 29.66 Cr in March 2022. The total operating income mirrored this trend, reaching 24.53 Cr in March 2025. The company's total expenditure, excluding depreciation, increased to 19.46 Cr in March 2025 from 17.73 Cr in March 2024. Operating profit (PBDIT) decreased to 7.32 Cr in March 2025 from 9.20 Cr in the previous year, while profit before tax rebounded to 2.76 Cr from a loss of 2.37 Cr in March 2024. Consequently, profit after tax also improved to 1.98 Cr from a loss of 3.23 Cr. The earnings per share (EPS) showed a positive turnaround, reaching 1.42 in March 2025 after being negative the previous year. On the balance sheet, total assets slightly increased to 82.17 Cr in March 2025, while total liabilities rose marginally to 82.17 Cr. The company maintained a stable equity capital of 13.90 Cr over the years. Cash flow from operating activities decreased to 2.00 Cr in March 2025, down from 5.00 Cr in March 2024, indicating challenges in cash generation despite the overall profit recovery.

What is the technical trend for Nidan Laborator.?

As of May 27, 2025, Nidan Laborator's technical trend is mildly bearish, influenced by mixed MACD signals and bearish Bollinger Bands.

As of 27 May 2025, the technical trend for Nidan Laborator has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish outlook. The daily moving averages are also mildly bearish. Bollinger Bands are bearish on both weekly and monthly time frames. The KST is mildly bullish weekly but bearish monthly, and there are no clear trends indicated by the Dow Theory or OBV. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from MACD and the bearish readings from Bollinger Bands.

Who are the top shareholders of the Nidan Laborator.?

The top shareholder of Nidan Laborator is Nitin Vitthalrao Thorve, holding 50.15% of shares. The highest public shareholder is Devendra Rajnikant Ladhani at 1.08%, while individual investors collectively own 39.78%.

The top shareholders of Nidan Laborator include the promoters, with Nitin Vitthalrao Thorve holding the largest share at 50.15%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Devendra Rajnikant Ladhani, who holds 1.08%. Additionally, individual investors collectively own 39.78% of the company.

When is the next results date for Nidan Laborator.?

No Upcoming Board Meetings

Has Nidan Laborator. declared dividend?

No Dividend History Available